中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2011年
24期
31-33
,共3页
谢朝辉%刘秀春%马胜禄%于忠华%展广宏%黄微%王薇
謝朝輝%劉秀春%馬勝祿%于忠華%展廣宏%黃微%王薇
사조휘%류수춘%마성록%우충화%전엄굉%황미%왕미
食管癌%紫杉醇%同步调强放射治疗
食管癌%紫杉醇%同步調彊放射治療
식관암%자삼순%동보조강방사치료
Esophageal Carcinoma%Paclitaxel chemotherapy%Intensity modulated radiation therapy
目的 探讨紫杉醇单药同步调强放疗治疗食管癌的近期疗效、局部控制率、生存率及不良反应.方法 103例食管癌患者根据入选标准随机分组,60例进入调强放疗+紫杉醇组(放化组),43例进入单纯调强放疗组(单放组).单放组采用调强放疗,95% PTV:66GY/30 ~ 33次,每周5次;放化组放疗从第1天即开始采用调强放射治疗,同时化疗(紫杉醇30 mg),第1、8、15、22、29、36天静脉滴注.结果 局部近期疗效放化组好于单放组,两组比较差异有统计学意义(P<0.05).放化疗组与单放组1、2年生存率,单放组为55.8%( 24/43)、32.5%( 14/43),同步放化组为86.6% (52/60)、68.3% (41/60).两组比较差异有统计学意义(P<0.05).不良反应放化组稍高于单放组,但两者比较差异无统计学意义.结论 紫杉醇单药每周方案同步调强放疗治疗食管癌近期疗效和局部控制率较好,能提高远期生存率,虽不良反应增加但能耐受.
目的 探討紫杉醇單藥同步調彊放療治療食管癌的近期療效、跼部控製率、生存率及不良反應.方法 103例食管癌患者根據入選標準隨機分組,60例進入調彊放療+紫杉醇組(放化組),43例進入單純調彊放療組(單放組).單放組採用調彊放療,95% PTV:66GY/30 ~ 33次,每週5次;放化組放療從第1天即開始採用調彊放射治療,同時化療(紫杉醇30 mg),第1、8、15、22、29、36天靜脈滴註.結果 跼部近期療效放化組好于單放組,兩組比較差異有統計學意義(P<0.05).放化療組與單放組1、2年生存率,單放組為55.8%( 24/43)、32.5%( 14/43),同步放化組為86.6% (52/60)、68.3% (41/60).兩組比較差異有統計學意義(P<0.05).不良反應放化組稍高于單放組,但兩者比較差異無統計學意義.結論 紫杉醇單藥每週方案同步調彊放療治療食管癌近期療效和跼部控製率較好,能提高遠期生存率,雖不良反應增加但能耐受.
목적 탐토자삼순단약동보조강방료치료식관암적근기료효、국부공제솔、생존솔급불량반응.방법 103례식관암환자근거입선표준수궤분조,60례진입조강방료+자삼순조(방화조),43례진입단순조강방료조(단방조).단방조채용조강방료,95% PTV:66GY/30 ~ 33차,매주5차;방화조방료종제1천즉개시채용조강방사치료,동시화료(자삼순30 mg),제1、8、15、22、29、36천정맥적주.결과 국부근기료효방화조호우단방조,량조비교차이유통계학의의(P<0.05).방화료조여단방조1、2년생존솔,단방조위55.8%( 24/43)、32.5%( 14/43),동보방화조위86.6% (52/60)、68.3% (41/60).량조비교차이유통계학의의(P<0.05).불량반응방화조초고우단방조,단량자비교차이무통계학의의.결론 자삼순단약매주방안동보조강방료치료식관암근기료효화국부공제솔교호,능제고원기생존솔,수불량반응증가단능내수.
Objective To evaluate the short- term efficacy,local control rates,survival rates and toxicity of concurrent paclitaxel chemotherapy and IMRT for esophageal carcinoma.Methods One hundred and three cases esophageal carcinoma patients were randomized in to two groups,60 cases was treated with concurrent IMCRT and paclitaxel chemotherapy ( named chemo - radiation group),another 43 cases with radiotherapy only (named radiotherapy group).All patients were irradiation 2.0 Gy/per fraction by planning target volume (PTV) 95 %,five fractions a week,the total radiation dose was 66 Gy in tumor.Besides,the chemo - radistion group was also received the concurrent chemotherapy with 60 mg of paclitaxel every Monday when radiation.Results The chemo -radiation group was more effective than radiotherapy group,and there was significant difference between the 2 groups (P < 0.05 ). 1 -year,2 - year survival rates of chemo - radiation group and radiation group were 86.6%,68.3% and 55.8%,32.5%,respectively,and there were significant differences between the two groups.Conclusions Concurrent paclitaxel chemotherapy and intensity modulated radiation therapy (IMRT) for esophageal carcinoma can improve the short- term efficacy and local control rate,and hence improve the longterm survival rate with lightly higher and tolerable toxicity.